iPSC‐derived human cardiac progenitor cells improve ventricular remodelling <i>via</i> angiogenesis and interstitial networking of infarcted myocardium

Ja, KP Myu Mia; Miao, Qingfeng; Tee, Nicole; Lim, Sze Yun; Nandihalli, Manasi; Ramachandra, Chrishan J A; Mehta, Ashish; Shim, Winston

doi:10.1111/jcmm.12725

Cited by 34 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Role of telocytes in the heart in health and diseases [Liskova et al, 2017] Arkh Patol c-kit Myocardial telocytes: a specific new cellular entity [Kostin, 2010] Telocytes form networks in normal cardiac tissues The failing human heart is characterized by decreased numbers of telocytes as result of apoptosis and altered extracellular matrix composition [Richter and Kostin, 2015] iPSC-derived human cardiac progenitor cells improve ventricular remodeling via angiogenesis and interstitial networking of infarcted myocardium [Ja et al, 2016] Cardiac telocytes as principal interstitial cells for myocardial reparation and regeneration after infarction -our hope [Varga et al, 2017a] Bratisl Lek Listy J Cell Mol Med Histol Histopathol…”

Section: The Markers Used To Identify Cardiac Tcs Can Be Challengedmentioning

confidence: 99%

Myocardial Telocyte-Like Cells: A Review Including New Evidence

Iancu

Rusu

Mogoantă

et al. 2018

Cells Tissues Organs

View full text Add to dashboard Cite

Telocytes (TCs) are a controversial cell type characterized by the presence of a particular kind of prolongations, known as telopodes, which are long, thin, and moniliform. A number of attempts has been made to establish the molecular phenotype of cardiac TCs (i.e., expression of c-kit, CD34, vimentin, PDGRFα, PDGRFβ, etc.). We designed an immunohistochemical study involving cardiac tissue samples obtained from 10 cadavers with the aim of determining whether there are TC-like interstitial cells that populate the interstitial space other than the mural microvascular cells. We applied the markers for CD31, CD34, PDGRFα, CD117/c-kit, and α-smooth muscle actin (α-SMA). We found that, in relation to two-dimensional cuts, the endothelial tubes could be misidentified as TC-like cells, the difference being the positive identification of endothelial lumina. Moreover, we found that cardiac pericytes express PDGRFα, CD117/c-kit, and α-SMA, and that they could also be misidentified as TCs when using light microscopy. We reviewed the respective values of the previously identified markers for achieving a clear-cut identification of cardiac TCs, highlighting the critical lack of specificity.

show abstract

Section: The Markers Used To Identify Cardiac Tcs Can Be Challengedmentioning

confidence: 99%

Myocardial Telocyte-Like Cells: A Review Including New Evidence

Iancu

Rusu

Mogoantă

et al. 2018

Cells Tissues Organs

View full text Add to dashboard Cite

show abstract

“…Despite the fact that this method seems to be unrelated to TCs, it was observed that 4 weeks after transplantation endogenous and exogenous cardiac TCs appeared and intermingled in the infarction zone. What is the most important is the fact that recovery of their network in ischaemic area coincided with increased angiogenesis and improvement of myocardial strain (43,44).…”

Section: Current Achievements Of Tcs-related Experimental Therapiesmentioning

confidence: 99%

A comprehensive guide to telocytes and their great potential in cardiovascular system

Kucybała¹,

Janas²,

Ciuk³

et al. 2017

BLL

View full text Add to dashboard Cite

Telocytes, a recently discovered type of interstitial cells, have a very distinctive morphology -the small cell body with long extensions, named telopodes. In our review, apart from introducing general aspects of telocytes, we focus on properties, functions and future potential of those cells in cardiovascular system. However, physiological functions of telocytes in cardiovascular system are still regarded as quite enigmatic. Previous studies claim that they play a role in organogenesis and regeneration, bioelectrical signalling, mechanoelectrical coupling, anti-oxidative protection, angiogenesis and regulation of blood fl ow. As well, they are presumably connected with the presence of blood-myocardium barrier and proper organisation of extracellular matrix. Moreover, there exists a signifi cant link between the quantity of telocytes in tissue and numerous cardiovascular diseases such as: myocardial infarction, cardiomyopathies, systemic sclerosis, heart failure, atrial fi brillation, isolated atrial amyloidosis, myxomatous valve degeneration and hyperplastic consequences of vascular injury. Thanks to their unique properties, telocytes might be a breakthrough in treatment of cardiovascular diseases, as they may be effective in reversing effects of myocardial infarction. Telocytes also may play a major role in tissue engineering -they might be the key factor in creating stable and effi cient vascular network in larger synthetic tissues or organs (Tab. 1, Fig. 3, Ref. 53). Text in PDF www.elis.sk.

show abstract

“…There are different types of stem cells such as embryonic stem cells, adult stem cells, and induced pluripotent stem cells for treatment of CVDs (Table 1). Previous studies have demonstrated therapeutic effects of ESCs differentiated into cardiomyocytes [17] and endothelial cells [18] for myocardial infarction, umbilical-cord-blood-derived MSCs for dilated cardiomyopathy [19], bone-marrow-derived-MSCs for cellular cardiomyoplasty [20], and iPSCs [21] and iPSCs-derived cardiovascular progenitor cells [22], endothelial progenitor cells (EPCs) [23], and cardiac stem cells [24] for myocardial infarction.…”

Section: Cardiovascular Diseases and Stem Cellsmentioning

confidence: 99%

Therapeutic Potential of Stem Cells Strategy for Cardiovascular Diseases

Lee

Kim

Ham

et al. 2016

Stem Cells International

View full text Add to dashboard Cite

Despite development of medicine, cardiovascular diseases (CVDs) are still the leading cause of mortality and morbidity worldwide. Over the past 10 years, various stem cells have been utilized in therapeutic strategies for the treatment of CVDs. CVDs are characterized by a broad range of pathological reactions including inflammation, necrosis, hyperplasia, and hypertrophy. However, the causes of CVDs are still unclear. While there is a limit to the currently available target-dependent treatments, the therapeutic potential of stem cells is very attractive for the treatment of CVDs because of their paracrine effects, anti-inflammatory activity, and immunomodulatory capacity. Various studies have recently reported increased therapeutic potential of transplantation of microRNA- (miRNA-) overexpressing stem cells or small-molecule-treated cells. In addition to treatment with drugs or overexpressed miRNA in stem cells, stem cell-derived extracellular vesicles also have therapeutic potential because they can deliver the stem cell-specific RNA and protein into the host cell, thereby improving cell viability. Here, we reported the state of stem cell-based therapy for the treatment of CVDs and the potential for cell-free based therapy.

show abstract

iPSC‐derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium

Cited by 34 publications

References 45 publications

Myocardial Telocyte-Like Cells: A Review Including New Evidence

Myocardial Telocyte-Like Cells: A Review Including New Evidence

A comprehensive guide to telocytes and their great potential in cardiovascular system

Therapeutic Potential of Stem Cells Strategy for Cardiovascular Diseases

Contact Info

Product

Resources

About